Peijia Medical Limited (9996.HK)

HKD 3.99

(1.53%)

Market Cap (In HKD)

2.61 Billion

Revenue (In HKD)

441.12 Million

Net Income (In HKD)

-392.52 Million

Avg. Volume

3.38 Million

Currency
HKD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
2.16-7.76
PE
-
EPS
-
Beta Value
0.515
ISIN
KYG6981F1090
CUSIP
G6981F109
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Medical - Devices
CEO
Dr. Yi Zhang
Employee Count
-
Website
https://www.peijiamedical.com
Ipo Date
2020-05-15
Details
Peijia Medical Limited engages in the research and development of transcatheter valve therapeutic and neuro interventional procedural medical devices. Its transcatheter valve therapeutic products include TaurusOne, a transcatheter aortic valve replacement (TAVR) system; TaurusElite, a retrievable TAVR system; TaurusNXT, a non-glutaraldehyde crosslinking dry-tissue TAVR system; TaurusWave, a lithotripsy valvuloplasty system; TaurusApex, a polymer leaflets TAVR system; Trilogy, a TAVR System; HighLife, a transseptal mitral value replacement system; SpyderOne, a transapical transcatheter mitral valve replacement (TMVR) system; Sutra, a TMV coaptation augmentation system; GeminiOne, a transcatheter edge-to-edge repair system; MonarQ and Peijia, which are transcatheter tricuspid valve replacement systems; TaurusAtlas, a transfemoral ballon catheter; TaurusExplora, a pre-shaped guidewire; and introducer sheath. The company also offers Jasper and Presgo, that are detachable coils; Jasper SS detachable coil; intracranial adjunctive stents; SacSpeed, a balloon dilatation catheter; Tethys AS, an aspiration catheter; Syphonet, a stent retriever; Neway, a balloon microcatheter; Fluxcap, a balloon guiding catheter; NeuroStellar, an intracranial stent; Presgo microcatheter and micro guidewire; Heralder guiding catheter and distal access catheter; Tethys, an intermediate catheter; and Jasper power supply. In addition, it engages in the trading business. Peijia Medical Limited was incorporated in 2012 and is headquartered in Suzhou, the People's Republic of China.